menu
    • menu
    [{"orgOrder":0,"company":"Custopharm","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Custopharm","amount2":0.42999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.42999999999999999,"dosageForm":"Injection","sponsorNew":"Custopharm \/ Hikma","highestDevelopmentStatusID":"12","companyTruncated":"Custopharm \/ Hikma"},{"orgOrder":0,"company":"Custopharm","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Custopharm","amount2":0.42999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.42999999999999999,"dosageForm":"Injection","sponsorNew":"Custopharm \/ Hikma","highestDevelopmentStatusID":"12","companyTruncated":"Custopharm \/ Hikma"}]

    Find Clinical Drug Pipeline Developments & Deals by Custopharm

    Menu

    Custopharm

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Custopharm

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Custopharm

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paracetamol

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : $425.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Hikma Completes Acquisition of Custopharm

                            Details : The combination with Custopharm enhances Hikma’s R&D capabilities and pipeline and expands Hikma’s differentiated US portfolio to close to 130 commercialised injectable medicines – a more than fivefold increase over the last decade, including Aceta...

                            Brand Name : Acetaminophen-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : $375.0 million

                            April 21, 2022

                            Lead Product(s) : Paracetamol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : $425.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Custopharm

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Custopharm

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paracetamol

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : $425.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Hikma Strengthens US Injectables Business Through Acquisition of Custopharm

                            Details : The combination with Custopharm enhances Hikma’s R&D capabilities and pipeline and expands Hikma’s differentiated US portfolio to close to 130 commercialised injectable medicines including Acetaminophen injection– a more than fivefold increase over...

                            Brand Name : Acetaminophen-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : $375.0 million

                            September 27, 2021

                            Lead Product(s) : Paracetamol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : $425.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth